Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
Infection. 2024 Feb;52(1):93-104. doi: 10.1007/s15010-023-02057-0. Epub 2023 Jul 11.
The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic causes a high burden of acute and long-term morbidity and mortality worldwide despite global efforts in containment, prophylaxis, and therapy. With unprecedented speed, the global scientific community has generated pivotal insights into the pathogen and the host response evoked by the infection. However, deeper characterization of the pathophysiology and pathology remains a high priority to reduce morbidity and mortality of coronavirus disease 2019 (COVID-19).
NAPKON-HAP is a multi-centered prospective observational study with a long-term follow-up phase of up to 36 months post-SARS-CoV-2 infection. It constitutes a central platform for harmonized data and biospecimen for interdisciplinary characterization of acute SARS-CoV-2 infection and long-term outcomes of diverging disease severities of hospitalized patients.
Primary outcome measures include clinical scores and quality of life assessment captured during hospitalization and at outpatient follow-up visits to assess acute and chronic morbidity. Secondary measures include results of biomolecular and immunological investigations and assessment of organ-specific involvement during and post-COVID-19 infection. NAPKON-HAP constitutes a national platform to provide accessibility and usability of the comprehensive data and biospecimen collection to global research.
NAPKON-HAP establishes a platform with standardized high-resolution data and biospecimen collection of hospitalized COVID-19 patients of different disease severities in Germany. With this study, we will add significant scientific insights and provide high-quality data to aid researchers to investigate COVID-19 pathophysiology, pathology, and chronic morbidity.
尽管全球在遏制、预防和治疗方面做出了努力,但严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)大流行仍在全球范围内造成了高负担的急性和长期发病率和死亡率。全球科学界以前所未有的速度对病原体以及感染引起的宿主反应产生了关键的认识。然而,更深入地描述病理生理学和病理学仍然是降低 2019 年冠状病毒病(COVID-19)发病率和死亡率的首要任务。
NAPKON-HAP 是一项多中心前瞻性观察研究,具有长达 36 个月的 SARS-CoV-2 感染后长期随访阶段。它构成了一个中央平台,用于协调数据和生物样本,以对急性 SARS-CoV-2 感染和住院患者不同疾病严重程度的长期结局进行跨学科特征描述。
主要结局测量包括住院期间和门诊随访期间捕获的临床评分和生活质量评估,以评估急性和慢性发病率。次要测量包括生物分子和免疫研究的结果以及 COVID-19 感染期间和之后对特定器官受累的评估。NAPKON-HAP 构成了一个国家平台,可提供对综合数据和生物样本收集的可及性和可用性,以进行全球研究。
NAPKON-HAP 为德国不同疾病严重程度的住院 COVID-19 患者建立了一个具有标准化高分辨率数据和生物样本采集的平台。通过这项研究,我们将提供有关 COVID-19 病理生理学、病理学和慢性发病率的重要科学见解,并提供高质量的数据,以帮助研究人员研究 COVID-19。